Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

"We look forward with great anticipation, the potential to report top-line results from the TRIUMPH study before the end of 2009," said Dr Fahar Merchant, President and CEO of Protox. "This is a significant milestone for the company and we are delighted with the rapid enrollment as it underscores the enthusiasm for PRX302 among the physician and patient communities."

TRIUMPH is the third BPH clinical trial of PRX302 conducted by Protox. In addition to being well-tolerated, the previous open-label Phase 2 study reported at the 2009 Annual Meeting of the American Urological Association, showed an 11 point improvement in the International Prostate Symptom Score at the optimal PRX302 dose used in the TRIUMPH study.

Source: PROTOX THERAPEUTICS INC.